Brian Magrane, MD
Family Medicine · Tavernier, FLNPI 1740228121
Payments from drug & device makers
What this record shows
The money is spread across several categories — consulting fees (51.5%), food and beverage and education — rather than concentrated in one kind of arrangement. 6 manufacturers reported payments, led by GSK at 55.2% of the total. Reporting peaked in 2019 at $348 and has fallen 94.0% since, to $21 in 2024. That places this record below the midpoint for family medicine clinicians in FL, where the typical reported total is $424.
Across 8 payments — averaging $54.66 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- GSK$241
- Amgen$82
- Philips North America LLC$57
- Pfizer$25
- Abbott$21
- AstraZeneca$12
What the payments were for
- Consulting fees$22551%
- Food & beverage$20146%
- Education$123%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| GSK | 2 | $241 |
| Amgen | 1 | $82 |
| Philips North America LLC | 1 | $57 |
| Pfizer | 2 | $25 |
| Abbott | 1 | $21 |
| AstraZeneca | 1 | $12 |
How this compares
$437 in reported general payments places this provider in the 50th percentile of 7,282 family medicine providers in Florida.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 78 | $98,602 |
| OzempicSemaglutide | 83 | $85,493 |
| JanuviaSitagliptin Phosphate | 26 | $31,405 |
| XareltoRivaroxaban | 19 | $22,255 |
| EntrestoSacubitril/Valsartan | 24 | $20,476 |
| JardianceEmpagliflozin | 17 | $13,926 |
| TrulicityDulaglutide | 15 | $13,705 |
| LinzessLinaclotide | 24 | $13,299 |
| SymbicortBudesonide/Formoterol Fumarate | 29 | $8,140 |
| Atorvastatin Calcium | 474 | $5,494 |
| Lantus SolostarInsulin Glargine,hum.Rec.Anlog | 24 | $4,117 |
| Tamsulosin Hcl | 157 | $3,584 |
| Losartan Potassium | 213 | $2,849 |
| PaxlovidNirmatrelvir/Ritonavir | 25 | $2,797 |
| Esomeprazole Magnesium | 30 | $2,595 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerEliquis, Paxlovid | $25 | $101,399103 claims |
| AstraZenecaSymbicort | $12 | $8,14029 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 50th percentile of 7,282 family medicine providers in Florida.
Other family medicine in Tavernier
- Noah LeeOakland Park$1.2M
- Angela RosselotBelle Isle$977K
- Richard LappOrlando$702K
- Hal BrownVero Beach$477K
- Lisa EvansBoca Raton$473K
- Giovana Rene CrooksBoca Raton$407K
- Edward BraunSt Petersburg$364K
- Samuel GreenleePensacola$235K
- Kevin FitzgeraldStuart$198K
- Louis KuritzkyGainesville$186K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.